These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30923991)

  • 21. [Drug treatment for chronic heart failure with reduced ejection fraction].
    Rickenbacher P
    Ther Umsch; 2011 Feb; 68(2):71-9. PubMed ID: 21271537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure.
    von Haehling S; Doehner W; Anker SD
    Cardiovasc Res; 2007 Jan; 73(2):298-309. PubMed ID: 17034772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating patients with severe heart failure.
    Eichhorn EJ
    Postgrad Med; 2002 Nov; 112(5 Suppl Unanswered):24-31. PubMed ID: 19667605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
    Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharma-clinics. How I treat...symptomatic heart failure].
    Kulbertus H
    Rev Med Liege; 1999 Jul; 54(7):625-8. PubMed ID: 10495687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2016 Mar; 34(3):373-84; discussion 384. PubMed ID: 26780184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.
    Moser DK; Biddle MJ
    Crit Care Nurs Clin North Am; 2003 Dec; 15(4):423-37, vii-viii. PubMed ID: 14717387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis and therapy approaches of cardiac cachexia.
    Springer J; Filippatos G; Akashi YJ; Anker SD
    Curr Opin Cardiol; 2006 May; 21(3):229-33. PubMed ID: 16601462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF].
    Vítovec J; Špinar J; Špinarová L
    Vnitr Lek; 2015 May; 61(5):470-4. PubMed ID: 26075858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart failure: recent advances in prevention and treatment.
    Fonarow GC
    Rev Cardiovasc Med; 2000; 1(1):25-33, 54. PubMed ID: 12457149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological modulations of the renin-angiotensin-aldosterone system in human congestive heart failure: effects on peripheral vascular endothelial function.
    Nakamura M
    Curr Vasc Pharmacol; 2004 Jan; 2(1):65-70. PubMed ID: 15320834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities.
    Ward RP; Anderson AS
    Postgrad Med; 2001 Mar; 109(3):36-8, 41-5. PubMed ID: 11265361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Medical management of chronic systolic heart failure].
    Galinier M
    Rev Prat; 2010 Sep; 60(7):941-6. PubMed ID: 21033491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
    Leong DP; McMurray JJV; Joseph PG; Yusuf S
    J Am Coll Cardiol; 2019 Aug; 74(5):683-698. PubMed ID: 31370961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction.
    Böhm M; Tschöpe C; Wirtz JH; Lokies J; Turgonyi E; Bramlage P; Lins K; Strunz AM; Tebbe U
    Clin Cardiol; 2015 Apr; 38(4):200-7. PubMed ID: 25733185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Neurohormonal factors in heart failure (and III)].
    Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
    Rev Esp Cardiol; 1996 Jun; 49(6):405-22. PubMed ID: 8753906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limitations of current medical therapies for the treatment of heart failure.
    Miller LW
    Rev Cardiovasc Med; 2003; 4 Suppl 2():S21-9. PubMed ID: 12776010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction.
    Khalid U; Deswal A
    Evid Based Med; 2013 Dec; 18(6):226-7. PubMed ID: 23585078
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.